Home
News
Videos
Podcasts
Slides
Visual Abstracts
Topics
Conferences
- SCAI 2018
- ACC 2018
- AHA 2017
- ESC 2017
- SCAI 2017
- ACC 2017

Preventing Heart Attack, Stroke, and Major Adverse Limb Events in Patients with Stable Atherosclerotic Vascular Disease

Dr. John Eikelboom Speaks at Brigham and Women’s Hospital

t f

FRESH –First-in-Class Aminopeptidase-A Inhibitor Firibastat Fails in Resistant Hypertension

Key Points Hypertension remains a major public health threat contributing significantly to rates of ischemic… Continue Reading

By Gabriel Pajares-Hurtado
November 7, 2022

The Diuretic Comparison Project (DCP): For hypertensive patients already on hydrochlorothiazide, switching to chlorthalidone does not improve outcomes

Key Points: Thiazide type diuretics are first-line medications for hypertension (HTN); while chlorthalidone (CTD) has… Continue Reading

By Lucas Marinacci
November 5, 2022

PROMINENT: Pemafibrate reduces triglyceride levels but not cardiovascular events in patients with dyslipidemia and T2DM

Key Points High triglyceride levels are associated with increased cardiovascular risk, but whether reductions in… Continue Reading

By Gabriel Pajares-Hurtado
November 5, 2022

Create an Account

CLICK TO REGISTER

Cardiology Now News is sponsored by the Baim Institute for Clinical Research and produced by the PERFUSE Study Group. Baim and PERFUSE are academic research organizations led by world class cardiovascular clinical trialists and opinion leaders.

Receive the latest news, interviews, podcasts directly to your inbox

More from Cardiovascular Prevention

FRESH –First-in-Class Aminopeptidase-A Inhibitor Firibastat Fails in Resistant Hypertension

The Diuretic Comparison Project (DCP): For hypertensive patients already on hydrochlorothiazide, switching to chlorthalidone does not improve outcomes

PROMINENT: Pemafibrate reduces triglyceride levels but not cardiovascular events in patients with dyslipidemia and T2DM